1
|
Iakovou I, Chrisoulidou A, Balaris V,
Balaris C, Doumas A and Karatzas N: Acute effects of recombinant
human TSH on bone markers in differentiated thyroid cancer. Hell J
Nucl Med. 13:208–212. 2010.PubMed/NCBI
|
2
|
Azizmohammadi Z, Tabei F, Shafiei B,
Babaei AA, Jukandan SM, Naghshine R, Javadi H, Nabipour I, Assadi M
and Asli IN: A study of the time of hospital discharge of
differentiated thyroid cancer patients after receiving iodine-131
for thyroid remnant ablation treatment. Hell J Nucl Med.
16:103–106. 2013.PubMed/NCBI
|
3
|
Chen G, Nicula D, Renko K and Derwahl M:
Synergistic anti-proliferative effect of metformin and sorafenib on
growth of anaplastic thyroid cancer cells and their stem cells.
Oncol Rep. 33:1994–2000. 2015.PubMed/NCBI
|
4
|
Scharpf J, Tuttle M, Wong R, Ridge D,
Smith R, Hartl D, Levine R and Randolph G: Comprehensive management
of recurrent thyroid cancer: An American Head and Neck Society
consensus statement: AHNS consensus statement. Head Neck. Sep
22–2016.(Epub ahead of print). doi: 10.1002/hed.24513. View Article : Google Scholar
|
5
|
Waldherr C, Schumacher T, Pless M,
Crazzolara A, Maecke HR, Nitzsche EU, Haldemann A and Mueller-Brand
J: Radiopeptide transmitted internal irradiation of non-iodophil
thyroid cancer and conventionally untreatable medullary thyroid
cancer using. Nucl Med Commun. 22:673–678. 2001. View Article : Google Scholar : PubMed/NCBI
|
6
|
Meng S, Wu H, Wang J and Qiu Q: Systematic
Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper
Mutations in Thyroid Cancer. Mol Inform. 35:495–505. 2016.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Rossi ED, Straccia P, Palumbo M, Stigliano
E, Revelli L, Lombardi CP, Santeusanio G, Pontecorvi A and Fadda G:
Diagnostic and prognostic role of HBME-1, galectin-3 and β-catenin
in poorly differentiated and anaplastic thyroid carcinomas. Appl
Immunohistochem Mol Morphol. 21:237–241. 2013.PubMed/NCBI
|
8
|
Barkalina N, Jones C, Townley H and Coward
K: Functionalization of mesoporous silica nanoparticles with a
cell-penetrating peptide to target mammalian sperm in vitro.
Nanomedicine (Lond). 10:1539–1553. 2015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Helmfors H, Eriksson J and Langel Ü:
Optimised luciferase assay for cell-penetrating peptide-mediated
delivery of short oligonucleotides. Anal Biochem. 484:136–142.
2015. View Article : Google Scholar : PubMed/NCBI
|
10
|
D'Alessio D, Giliberti C, Benassi M and
Strigari L: Potential third-party radiation exposure from patients
undergoing therapy with 131I for thyroid cancer or
metastases. Health Phys. 108:319–325. 2015. View Article : Google Scholar : PubMed/NCBI
|
11
|
Gautam A, Chaudhary K, Kumar R, Sharma A,
Kapoor P and Tyagi A: Open source drug discovery consortium Raghava
GP In silico approaches for designing highly effective cell
penetrating peptides. J Transl Med. 11:742013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Cazarin JM, Andrade BM and Carvalho DP:
AMP-activated protein kinase activation leads to lysome-mediated
NA(+)/I(−)-symporter protein degradation in rat thyroid cells. Horm
Metab Res. 46:313–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Merron A, Peerlinck I, Martin-Duque P,
Burnet J, Quintanilla M, Mather S, Hingorani M, Harrington K, Iggo
R and Vassaux G: SPECT/CT imaging of oncolytic adenovirus
propagation in tumours in vivo using the Na/I symporter as a
reporter gene. Gene Ther. 14:1731–1738. 2007. View Article : Google Scholar : PubMed/NCBI
|
14
|
Kurebayashi J, Tanaka K, Otsuki T, Moriya
T, Kunisue H, Uno M and Sonoo H: All-trans-retinoic acid modulates
expression levels of thyroglobulin and cytokines in a new human
poorly differentiated papillary thyroid carcinoma cell line, KTC-1.
J Clin Endocrinol Metab. 85:2889–2896. 2000. View Article : Google Scholar : PubMed/NCBI
|
15
|
Modoni S, Landriscina M, Fabiano A,
Fersini A, Urbano N, Ambrosi A and Cignarelli M: Reinduction of
cell differentiation and 131I uptake in a poorly differentiated
thyroid tumor in response to the reverse transcriptase (RT)
inhibitor nevirapine. Cancer Biother Radiopharm. 22:289–295. 2007.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Said M, Fujimoto M, Franken C, Woo S,
Vuong B and Haigh PI: Preferential use of total thyroidectomy
without prophylactic central lymph node dissection for early-stage
papillary thyroid cancer: Oncologic outcomes in an integrated
health plan. Perm J. 20:15–251. 2016.
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Kist JW, de Keizer B, Stokkel MP, Hoekstra
OS and Vogel WV: THYROPET study group: Recurrent differentiated
thyroid cancer: Towards personalized treatment based on evaluation
of tumor characteristics with PET (THYROPET Study): Study protocol
of a multicenter observational cohort study. BMC Cancer.
14:4052014. View Article : Google Scholar : PubMed/NCBI
|
19
|
Kundu P, Lata S, Sharma P, Singh H,
Malhotra A and Bal C: Prospective evaluation of (68)Ga-DOTANOC
PET-CT in differentiated thyroid cancer patients with raised
thyroglobulin and negative (131)I-whole body scan: Comparison with
(18)F-FDG PET-CT. Eur J Nucl Med Mol Imaging. 41:1354–1362. 2014.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Ghofrani M, Sosa JA, Ocal IT and Angeletti
C: Fine needle aspiration of poorly differentiated oxyphilic
(Hurthle cell) thyroid carcinoma: A case report. Acta Cytol.
50:560–562. 2006. View Article : Google Scholar : PubMed/NCBI
|
21
|
Sherman SI, Clary DO, Elisei R,
Schlumberger MJ, Cohen EE, Schöffski P, Wirth LJ, Mangeshkar M,
Aftab DT and Brose MS: Correlative analyses of RET and RAS
mutations in a phase 3 trial of cabozantinib in patients with
progressive, metastatic medullary thyroid cancer. Cancer. Aug
15–2016.(Epub ahead of press). doi: 10.1002/cncr.30252. View Article : Google Scholar
|
22
|
Liepe K: Sensitivity of preparation with
rhTSH or thyroid hormone withdrawal using 131I-whole
body scans to identify metastases of differentiated thyroid cancer.
Int J Surg. 16:107–112. 2015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Vilasdechanon N, Ua-Apisitwong S,
Chatnampet K, Ekmahachai M and Vilasdechanon J: Design of patient
rooms and automatic radioiodine-131 waste water management system
for a thyroid cancer treatment ward: ‘Suandok Model’. J Radiol
Prot. 34:699–708. 2014. View Article : Google Scholar : PubMed/NCBI
|
24
|
Turba UC, Sildiroglu O and Rehm PK:
Radioiodine (131I) accumulation in bronchogenic cyst in the setting
of thyroid carcinoma remission. Clin Imaging. 36:224–227. 2012.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Bastos AU, Oler G, Nozima BH, Moyses RA
and Cerutti JM: BRAF V600E and decreased NIS and TPO expression are
associated with aggressiveness of a subgroup of papillary thyroid
microcarcinoma. Eur J Endocrinol. 173:525–540. 2015. View Article : Google Scholar : PubMed/NCBI
|
26
|
D'Alessio D, Giliberti C, Benassi M and
Strigari L: Potential third-party radiation exposure from patients
undergoing therapy with 131I for thyroid cancer or metastases.
Health Phys. 108:319–325. 2015. View Article : Google Scholar : PubMed/NCBI
|
27
|
de la Chapelle A and Jazdzewski K:
MicroRNAs in thyroid cancer. J Clin Endocrinol Metab. 96:3326–3336.
2011. View Article : Google Scholar : PubMed/NCBI
|
28
|
Duman BB, Kara OI, Uğuz A and Ates BT:
Evaluation of PTEN, PI3K, MTOR and KRAS expression and their
clinical and prognostic relevance to differentiated thyroid
carcinoma. Contemp Oncol (Pozn). 18:234–240. 2014.PubMed/NCBI
|
29
|
Yun F, Jia Y, Li X, Yuan L, Sun Q, Yu H,
Shi L and Yuan H: Clinicopathological significance of PTEN and
PI3K/AKT signal transduction pathway in non-small cell lung cancer.
Int J Clin Exp Pathol. 6:2112–2120. 2013.PubMed/NCBI
|
30
|
Biswas R, Mondal A and Ahn JC:
Deregulation of EGFR/PI3K and activation of PTEN by photodynamic
therapy combined with carboplatin in human anaplastic thyroid
cancer cells and xenograft tumors in nude mice. J Photochem
Photobiol B. 148:118–127. 2015. View Article : Google Scholar : PubMed/NCBI
|